Onkologie. 2021:15(3):119-122 | DOI: 10.36290/xon.2021.022

New Treatment Options for Cervical Cancer

Lucie Mouková
Oddělení gynekologické onkologie, Klinika operační onkologie, Masarykův onkologický ústav, Brno

Primary treatment for cervical cancer is surgery in the early stages. In the adjuvant, in primary inoperable patients or in the case of advanced stages of cancer, radiotherapy is chosen. In case of recurrences or progressive tumours, the prognosis is unfavourable despite chemotherapy. Currently, biological treatment with bevacizumab is approved in patients with metastatic, recurrent or persistent cancer. Immunotherapy is in the research phase.

Keywords: uterine cervix carcinoma, bevacizumab, systemic treatment, immunotherapy.

Published: May 6, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mouková L. New Treatment Options for Cervical Cancer. Onkologie. 2021;15(3):119-122. doi: 10.36290/xon.2021.022.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cibula D, Petruželka L, et al. Nádory děložního hrdla: Onkogynekologie, Praha: Grada, 1. vydání 2009: 393-456.
    2. Šlampa P , et al. Radiační onkologie v praxi. Brno: MOÚ, 2007: 118-126.
    3. www.ema.europa.eu/en/documents/overview/avastin-epar-summary-public_cs.pdf.
    4. http://www.sukl.cz/modules/medication/detail.php?code=0028397&tab=prices.
    5. Správní řízení SUKLS71238/2020, rozhodnutí ze dne: 27. 7. 2020, Souhrn údajů o přípravku Avastin ze dne 25. 2. 2020.
    6. Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 2017; 390(10103): 1654-1663. Go to original source... Go to PubMed...
    7. Zikán M. Využití bavacizumabu (Avastin) v léčbě recidivujícího karcinomu děložního hrdla. Onkologie 2017; 11(5): 264-268. Go to original source...
    8. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endo-thelial growth factor is a secreted angiogenic mitogen. Sci-ence 1989; 246: 1306-9.4. Go to original source... Go to PubMed...
    9. Monk BJ, Sill MW, Burger RA, et al. Phase II trial of bevaci-zumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2009; 27: 1069-1074. Go to original source... Go to PubMed...
    10. Sirák I, Hodek M, Zoul Z. Systémová terapie v léčbě karcinomu děložního hrdla. Onkologie 2017; 11(2): 78-78. Go to original source...
    11. Vora C, Gupta S, Targeted therapy in cervical cancer, ESMO Open 2019; 3: e000462. Go to original source... Go to PubMed...
    12. Kagabu M, Nagasava T, Fukagawa D, et al. Immunotherapy for Uterine Cervical Cancer. Healthcare 2019; 7(3): 108. Go to original source... Go to PubMed...
    13. Cheng-Tao L, Caho-Nin W, Chyong-Huey L. Immunotherapy for advanced or relapsed cervical cancer. Gynecology and Minimally Invasive Therapy 2013; 2(1): 3-7. Go to original source...
    14. Li Y, Liu S, Margolin K, Hwu P. Summary of the primer on tumor immunology and the biological therapy of cancer. J Transl Med 2009; 7: 11. Go to original source... Go to PubMed...
    15. Liu C, Lu J, Tian H, et al. Increased expression of PDL1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity. Mol. Med. Rep. 2017; 15: 1063-1070. Go to original source... Go to PubMed...
    16. Basu P, Mehta A, Jain M, et al. A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes-Listeriolysin O Immunotherapy with or without Cisplatin in Treatment of Advanced Cervical Cancer. Int. J. Gynecol. Cancer 2018; 28: 764-772. Go to original source... Go to PubMed...
    17. Massarelli E, William W, Johnson F, et al. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients with Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019; 5: 67-73. Go to original source... Go to PubMed...
    18. Jonathan A, Trujillo RF, Sweis RB, et al. T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol. Res. 2018; 6(9): 990-1000. Go to original source...
    19. Cancer Genome Atlas Research Network; Albert Einstein College of Medicine; Analytical Biological Services; Barretos Cancer Hospital; Baylor College of Medicine; Beckman Research Institute of City of Hope; Buck Institute for Research on Aging; Canada's Michael Smith Genome Sciences Centre; Harvard Medical School; Helen, F. Graham Cancer Center &Research Institute at Christiana Care Health Services; et al. Integrated genomic and molecular characterization of cervical cancer. Nature 2017; 543: 378-384. Go to original source... Go to PubMed...
    20. Suchý D. Imunitně podmíněné nežádoucí účinky inhibitorů kontrolních bodů, Klin Farmakol Farm 2019; 33(3): 20-24. Go to original source...
    21. Meng Y, Liang H, Hu J, Liu S et al. PD-L1 Expression Correlates with Tumor Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Cervical Cancer. J. Cancer 2018; 9: 2938-2945. Go to original source... Go to PubMed...
    22. Feng Y C, Ji W L, Yue N, et al. The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance. Cancer Manag. Res. 2018; 10: 105-113. Go to original source... Go to PubMed...
    23. Mezache L, Paniccia B, Nyinawabera A, et al. Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod. Pathol. 2015; 28: 1594-1602. Go to original source... Go to PubMed...
    24. Frenel JS, Le Tourneau C, O'Neil B, Ott A, et al. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. J. Clin. Oncol. 2017; 35: 4035-4041. Go to original source... Go to PubMed...
    25. Schellens J H M, Marabelle A, Zeigenfuss S, et al. Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE-158 study. J Clin Oncol. 2017; 35(15). Go to original source...
    26. Hollebecque A, Meyer T, Moore KN, et al. An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers. J. Clin. Oncol. 2017; 35(15). Go to original source...
    27. Mayadev J, Brady WE, Lin YG, et al. A phase I study of sequential ipilimumab in the definitive treatment of node positive cervical cancer: GOG 9929. J Clin Oncol 2017; 35(15): 5526. Go to original source...
    28. Van Vloten JP, Workenhe ST, Wootton SK, et al. Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies. J. Immunol. 2018; 200: 450-458. Go to original source... Go to PubMed...
    29. Lakomý R, Poprach A. Nežádoucí účinky moderní imunoterapie a jejich řešení v klinické praxi. Klin Onkol 2015; 28(4): 4S103-4S114. Go to original source...
    30. Johnson DB, Chandra S, Sosman JA. Immune Checkpoint Inhibitor Toxicity in 2018. JAMA 2018; 320(16): 1702-1703. Go to original source... Go to PubMed...
    31. Noha AW, Alshawa A, SuarezAlmazor ME. Adverse Events in Cancer Immunotherapy. In: Naing, J. Hajjar (eds.). Immunotherapy, Advances in Experimental Medicine and Biology, 995.
    32. June CH, Sadelain M, Chimeric Antigen Receptor Therapy. N. Engl. J. Med. 2018; 379: 64-73. Go to original source... Go to PubMed...
    33. Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci. 2016; 107: 1373-1379. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.